SSG
ARQT icon

Summit Securities Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Summit Securities Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-822
Closed -$23.9K – 1048
2025
Q4 		$23.9K Buy
+822
New +$21K ﹤0.01% 771

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Polar Capital Holdings
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Summit Securities Group's ARQT Position: Q1 2026 in Review

Summit Securities Group sold out of Arcutis Biotherapeutics (ARQT) in Q1 2026, closing a stake of 822 shares — an estimated $23.9K sold.

Summit Securities Group first reported a position in ARQT in Q4 2025 and held it in 1 quarter. The position peaked at $23.9K in Q4 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Summit Securities Group reported no remaining Arcutis Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Summit Securities Group sold 822 Arcutis Biotherapeutics shares in Q1 2026, an estimated $23.9K.
  • Summit Securities Group first reported a position in Arcutis Biotherapeutics in Q4 2025 and held it in 1 quarter.
  • Summit Securities Group's Arcutis Biotherapeutics position peaked at $23.9K in Q4 2025.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.